Hidden army within:Harnessing the microbiome to improve cancer treatment outcomes  

作　　者：Ippokratis Messaritakis Georgios Vougiouklakis Asimina Koulouridi Aris P Agouridis Nikolaos Spernovasilis 

机构地区：[1]Department of Microbiology,German Oncology Center&Yiannoukas Labs LTD,Bioiatriki Group,Limassol 4108,Cyprus [2]Department of Internal Medicine,German Oncology Center,Limassol 4108,Cyprus [3]Department of Oncology,German Oncology Center,Limassol 4108,Cyprus [4]School of Medicine,European University Cyprus,Nicosia 2404,Cyprus [5]Department of Infectious Diseases,German Oncology Center,Limassol 4108,Cyprus

出　　处：《World Journal of Clinical Cases》2024年第28期6159-6164,共6页世界临床病例杂志

摘　　要：The gut microbiome has emerged as a critical player in cancer pathogenesis and treatment response.Dysbiosis,an imbalance in the gut microbial community,impacts tumor initiation,progression,and therapy outcomes.Specific bacterial species have been associated with either promoting or inhibiting tumor growth,offering potential targets for therapeutic intervention.The gut microbiome in-fluences the efficacy and toxicity of conventional treatments and cutting-edge immunotherapies,highlighting its potential as a therapeutic target in cancer care.However,translating microbiome research into clinical practice requires addres-sing challenges such as standardizing methodologies,validating microbial bio-markers,and ensuring ethical considerations.Here,we provide a comprehensive overview of the gut microbiome's role in cancer highlighting the need for on-going research,collaboration,and innovation to harness its full potential for im-proving patient outcomes in oncology.The current editorial aims to explore these insights and emphasizes the need for standardized methodologies,validation of microbial biomarkers,and interdisciplinary collaboration to translate microbiome research into clinical applications.Furthermore,it underscores ethical consider-ations and regulatory challenges surrounding the use of microbiome-based the-rapies.Together,this article advocates for ongoing research,collaboration,and innovation to realize the full potential of microbiome-guided oncology in impro-ving patient care and outcomes.

关 键 词：Gut microbiome Cancer treatment IMMUNOTHERAPY Microbiome-based interventions DYSBIOSIS Precision oncology 

分 类 号：R730.5[医药卫生—肿瘤]